Kynmobi (Anhydrous Apomorphine Hydrochloride)

Apomorphine, the active ingredient in Kynmobi, is a non‑selective dopamine D1/D2 receptor agonist. By directly activating these receptors in the brain, it bypasses the need for endogenous dopamine and quickly restores dopaminergic signaling, alleviating motor impairment.

The prescribed dose of Kynmobi is individualized by the treating physician. The prescriber determines the appropriate strength, frequency, and titration schedule based on the patient’s clinical response and tolerance.

The safety of Kynmobi in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Kynmobi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kynmobi offers a rapid, sublingual route of administration, which can be faster than oral levodopa or transdermal therapies. It is particularly useful for patients who need immediate relief of OFF episodes, whereas other dopamine agonists may have slower onset or require different dosing schedules.

Kynmobi should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the film’s stability and ensures consistent drug delivery.

Kynmobi is a sublingual film placed under the tongue. The film dissolves rapidly, allowing the drug to be absorbed directly into the bloodstream through the oral mucosa, providing quick onset of action without the need for swallowing.

Serious risks include severe hypotension, syncope, hallucinations or psychosis, impulse control disorders, and cardiac arrhythmias. Patients should be monitored closely for these events, especially during dose titration or when combined with other cardiovascular or psychiatric medications.

Kynmobi is contraindicated in patients with severe cardiac disease, uncontrolled hypertension, known hypersensitivity to apomorphine, or those taking monoamine oxidase inhibitors. It should also be used with caution in individuals with a history of psychosis or impulse control disorders.